The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study

Belinda Lee, Hui-Li Wong, Mark Tacey, Jeanne Tie, Rachel Wong, Margaret Lee, Louise Nott, Jeremy Shapiro, Ross Jennens, Natalie Turner, Ben Tran, Sumitra Ananda, Desmond Yip, Gary Richardson, Phillip Parente, Lionel Lim, Greg Stefanou, Matthew Burge, Mahesh Iddawela, Jeremy PowerPeter Gibbs

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


Background: Debate continues regarding the benefits versus risks of initial resection of the primary tumor in metastatic colorectal cancer (mCRC) patients with an asymptomatic primary tumor. Although the benefit of the anti-vascular endothelial growth factor agent bevacizumab alongside first-line chemotherapy in mCRC is established, the impact of bevacizumab on the intact primary tumor (IPT) is less well understood. Methods: Data from an Australian mCRC registry were used to assess the impact of bevacizumab-based regimens in the presence of an IPT, to see if this differs from effects in resected primary tumor (RPT) patients and to understand the safety profile of bevacizumab in patients with IPT. Progression-free survival (PFS), overall survival (OS) and safety endpoints were analyzed. Results: Of 1204 mCRC patients, 826 (69%) were eligible for inclusion. Bevacizumab use was similar in both arms (IPT (64%) versus RPT (70%)); compared with chemotherapy alone, bevacizumab use was associated with significantly longer PFS (IPT: 8.5 months vs 4.7 months, P = 0.017; RPT: 10.8 months vs 5.8 months, P < 0.001) and OS (IPT: 20 months vs 14.8 months, P = 0.005; RPT: 24.4 months vs 17.3 months, P = 0.004)).1 Bevacizumab use in an IPT was associated with more GI perforations (4.5% vs 1.8%, P = 0.210) but less frequent bleeding (1.5% vs 5.3%, P = 0.050) and thrombosis (1.5% vs 2.7%, P = 0.470), versus chemotherapy alone. Median survival was equivalent between patients that did or did not experience bevacizumab-related adverse events - 20.0 months versus 19.9 months, hazard ratio = 0.98, P = 0.623.1 Conclusions: The addition of bevacizumab significantly improved survival outcomes in mCRC with an IPT. The occurrence of bevacizumab-related adverse events did not significantly impact survival outcomes.

Original languageEnglish
Pages (from-to)314-321
Number of pages8
JournalAsia-Pacific Journal of Clinical Oncology
Issue number4
Publication statusPublished - Aug 2017


  • Anti-VEGF therapy
  • Colorectal cancer
  • Drug safety
  • GI perforation rate
  • Primary tumor resection

Cite this